You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Mallinckrodt
Moodys
Dow
Merck

Last Updated: February 23, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,292,990


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,292,990 protect, and when does it expire?

Patent 10,292,990 protects YONSA and is included in one NDA.

This patent has thirty-seven patent family members in twenty-one countries.

Summary for Patent: 10,292,990
Title:Abiraterone steroid formulation
Abstract: A nanoparticulate composition of abiraterone acetate that allows treatment at a lower dose than convention abiraterone acetate formulations is described as in a method of treating prostate cancer by administering the composition together with a glucocorticoid.
Inventor(s): Nemeth; Paul (Philadelphia, PA), Callahan; Matt (Penn Valley, PA), Bosch; H. William (Bryn Mawr, PA), Norret; Marck (Darlington, AU)
Assignee: SUN PHARMA GLOBAL FZE (Sharjah, AE)
Application Number:15/345,410
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Drugs Protected by US Patent 10,292,990

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sun Pharma Global YONSA abiraterone acetate TABLET;ORAL 210308-001 May 22, 2018 RX Yes Yes   Start Trial   Start Trial USE IN COMBINATION WITH METHYLPREDNISOLONE FOR THE TREATMENT OF PATIENTS WITH PROSTATE CANCER   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,292,990

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 095480   Start Trial
Australia 2014232508   Start Trial
Australia 2015317466   Start Trial
Australia 2018241103   Start Trial
Brazil 112015023629   Start Trial
Brazil 112017003219   Start Trial
Canada 2907415   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Johnson and Johnson
Colorcon
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.